

Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function

The US POINTER Randomized Clinical Trial

Laura D. Baker, PhD; Mark A. Espeland, PhD; Rachel A. Whitmer, PhD; Heather M. Snyder, PhD; Xiaoyan Leng, MD, PhD; Laura Lovato, MS; Kathryn V. Papp, PhD; Melissa Yu, MD; Miia Kivipelto, MD, PhD; Ashley S. Alexander, MHSA; Susan Antkowiak, BS; Maryjo Cleveland, MD; Claire Day, BSW; Richard Elbein, MS; Sarah Tomaszewski Farias, PhD; Deborah Felton, BS; Katelyn R. Garcia, MS; Darren R. Gitelman, MD; Sarah Graef, DC; Marjorie Howard, MSPH; Jeffrey Katula, PhD; Katherine Lambert, BA; Olivia Matongo, MPH; Anne Marie McDonald, MEd, MBA; Valory Pavlik, PhD; Rema Raman, PhD; Stephen Salloway, MD, MS; Christy Tangney, PhD; Jennifer Ventrelle, MS; Sharon Wilmoth, BA; Benjamin J. Williams, MD, PhD; Rena Wing, PhD; Nancy Woolard; Maria C. Carrillo, PhD

IMPORTANCE Identifying new interventions to slow and prevent cognitive decline associated with dementia is critical. Nonpharmacological interventions targeting modifiable risk factors are promising, relatively low-cost, accessible, and safe approaches.

OBJECTIVE To compare the effects of two 2-year lifestyle interventions on cognitive trajectory in older adults at risk of cognitive decline and dementia.

DESIGN, SETTING, AND PARTICIPANTS Single-blind, multicenter randomized clinical trial enrolling 2111 participants from May 2019 to March 2023 (final follow-up, May 14, 2025) at 5 clinical sites in the US. Participant inclusion criteria enriched risk of cognitive decline and included age 60 to 79 years, sedentary lifestyle, and suboptimal diet plus at least 2 additional criteria related to family history of memory impairment, cardiometabolic risk, race and ethnicity, older age, and sex.

INTERVENTIONS Participants were randomly assigned with equal probability to structured (n = 1056) or self-guided (n = 1055) interventions. Both interventions encouraged increased physical and cognitive activity, healthy diet, social engagement, and cardiovascular health monitoring, but differed in structure, intensity, and accountability.

MAIN OUTCOMES AND MEASURES The primary comparison was difference between intervention groups in annual rate of change in global cognitive function, assessed by a composite measure of executive function, episodic memory, and processing speed, over 2 years.

RESULTS Among the 2111 individuals enrolled (mean age, 68.2 [SD, 5.2] years; 1455 [68.9%] female), 89% completed the year 2 assessment. The mean global cognitive composite z score increased from baseline over time in both groups, with a mean rate of increase per year of 0.243 SD (95% CI, 0.227-0.258) for the structured intervention and 0.213 SD (95% CI, 0.198-0.229) for the self-guided intervention. The mean rate of increase per year was statistically significantly greater for the structured group than the self-guided group by 0.029 SD (95% CI, 0.008-0.050; $P = .008$). Based on prespecified secondary subgroup comparisons, the structured intervention benefit was consistent for *APOE* $\epsilon 4$ carriers and noncarriers ($P = .95$ for interaction) but appeared greater for adults with lower vs higher baseline cognition ($P = .02$ for interaction). Fewer ascertained adverse events were reported in the structured group (serious: 151; nonserious: 1091) vs the self-guided group (serious: 190; nonserious: 1225), with a positive COVID-19 test result being the most common adverse event overall and more frequent in the structured group.

CONCLUSIONS AND RELEVANCE Among older adults at risk of cognitive decline and dementia, a structured, higher-intensity intervention had a statistically significant greater benefit on global cognition compared with an unstructured, self-guided intervention. Further investigation of functional outcomes, biomarkers, and ongoing extended follow-up will help address clinical relevance and sustainability of the observed cognitive benefits.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: [NCT03688126](https://clinicaltrials.gov/ct2/show/study/NCT03688126)

JAMA. doi:[10.1001/jama.2025.12923](https://doi.org/10.1001/jama.2025.12923)
Published online July 28, 2025.

- [+ Visual Abstract](#)
- [+ Editorial](#)
- [+ Supplemental content](#)

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Authors: Laura D. Baker, PhD (laura.d.baker@advocatehealth.org), and Mark A. Espeland, PhD (mark.espeland@advocatehealth.org), One Medical Center Blvd, Sticht Center on Aging and Alzheimer's Prevention, Winston-Salem, NC 27157.

Identifying efficacious interventions to slow or prevent cognitive decline associated with Alzheimer disease (AD) and related dementias is a major public health priority due to the growing number of affected individuals and the profound economic, psychological, and social burdens of the disease.¹ Late-life cognitive decline is often attributable to mixed pathology,² and effective treatment will likely require a multipronged therapeutic strategy to address multiple mechanisms associated with AD and vascular disease, among others. Thus, there is a critical need for interventions that target several risk pathways simultaneously. Recent advances in anti-amyloid therapeutics show evidence for slowing of AD-specific clinical progression.³⁻⁵ These treatments are approved for individuals with confirmed AD pathology, specifically those with mild cognitive impairment or mild dementia and a positive amyloid biomarker.⁶ Although they have been shown to effectively remove β -amyloid, they do not address vascular pathologies such as infarcts and arteriosclerosis that increase risk of cognitive decline and dementia and that are highly prevalent in older adult populations. There remains a significant need for better treatments and for therapies that can impact AD and related dementias more broadly.

Nonpharmacological strategies targeting modifiable risk factors offer a promising, low-cost, accessible, and safe approach. The latest *Lancet* Commission report on dementia prevention⁷ identified 14 modifiable risk factors that, if addressed, could potentially reduce dementia incidence by 45%. Multidomain lifestyle interventions addressing multiple pathways have proliferated since the landmark 2015 Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER).⁸ FINGER demonstrated significant cognitive benefit after 2 years of multidomain intervention in older adults at elevated risk of AD and related dementias. The World-Wide FINGERS (WW-FINGERS) network was launched in 2017 to foster global collaboration, protocol alignment, and data sharing across nonpharmacological risk reduction trials.⁹ Additional multidomain lifestyle trials have been conducted,¹⁰⁻¹⁷ although some have not demonstrated benefit.¹³⁻¹⁶ Differences in trial protocols (eg, sample, intervention intensity, participant support, outcomes) likely explain variability and underscore the need for harmonization.¹⁸

The US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (US POINTER) was developed to assess whether FINGER results generalize to a larger, more diverse US population at risk of dementia, using culturally adapted protocols.¹⁹ The primary aim of this randomized 2-year clinical trial was to compare the effects of 2 multimodal lifestyle interventions on global cognitive function in 2000 at-risk older adults.

Methods

Trial Design and Oversight

The study design and methods are published,¹⁹ and the trial protocol and statistical analysis plan are available in [Supplement 1](#) and [Supplement 2](#), respectively. An overview of screening, enrollment, and the interventions is provided in

Key Points

Question Can multidomain lifestyle interventions improve or protect cognitive function in older adults at risk of cognitive decline and dementia?

Findings In this randomized clinical trial of 2111 older adults at risk of cognitive decline and dementia, a structured lifestyle intervention of regular moderate- to high-intensity physical exercise, adherence to the MIND diet, cognitive challenge and social engagement, and cardiovascular health monitoring led to a statistically significant greater improvement in global cognition over 2 years relative to a lower-intensity self-guided intervention (mean composite z-score increase of 0.243 SD per year vs 0.213 SD per year, respectively).


Meaning The structured, higher-intensity intervention had a greater benefit on global cognition than the self-guided, low-intensity intervention. Further research is needed to understand clinical significance and longer-term cognitive effects of both interventions.

Figure 1. US POINTER was a phase 3, 5-site, 2-year, single-blind randomized clinical trial of 2 lifestyle interventions in older adults at risk of dementia due to established demographic, lifestyle, family history, and cardiometabolic factors.²⁰ A central institutional review board at Wake Forest University School of Medicine approved the study. All participants provided written informed consent. The trial was conducted in accordance with established ethical standards. An external, independent data and safety monitoring board provided safety oversight. We followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline for nonpharmacological trials.²¹

Participants

Participants were recruited via electronic health records and grassroots engagement leveraging local community partnerships for assistance.¹⁹ Eligibility criteria were designed to identify cognitively asymptomatic older adults at elevated risk of cognitive decline and dementia.¹⁹ Participants were 60 to 79 years old, were sedentary (per the modified Telephone Assessment of Physical Activity: less than 60 minutes per week at moderate intensity), and had a suboptimal diet (Mediterranean-DASH Intervention for Neurodegenerative Delay [MIND] diet screener: ≤ 9 of 14 points), plus 2 of the following: first-degree family history of memory impairment; elevated cardiometabolic risk (systolic blood pressure ≥ 125 mm Hg, low-density lipoprotein cholesterol ≥ 115 mg/dL [2.98 mmol/L], or hemoglobin A_{1c} $\geq 6.0\%$); self-identified American Indian or Alaska Native, Black, African American, or African, or Middle Eastern or North African race; Hispanic, Latinx, or Spanish ethnicity; age 70 to 79 years; or male sex. Race and ethnicity were self-reported via questionnaire, allowing multiple fixed-category selections, including “none of the above describes me,” which was coded as “other.” This information was collected to support the study objective of enhancing generalizability through enrollment of a diverse and representative cohort. Key exclusions included

Figure 1. Recruitment and Enrollment Stages of US POINTER and Overview of Multidomain Interventions



Recruitment relied on a 3-stage process (panel A) that included outreach through electronic health records, site registries, and community partners to engage interested individuals (screening stage 1), who then received mailed study information and hard-copy or online questionnaires to assess eligibility (screening stage 2). Screening stage 3 was completed by telephone for cognitive screening and to confirm sedentary status. The 3-stage enrollment

process included baseline assessment to confirm eligibility (enrollment stage 1), randomization (enrollment stage 2), and participants are notified of peer team assignment (enrollment stage 3). Panel B provides an overview of activities and expectations for the structured and self-guided intervention groups. MIND indicates Mediterranean-DASH Intervention for Neurodegenerative Delay.

neurological/psychiatric disorders, significant systemic disease, use of cognition-altering medications, or cognitive impairment (modified Telephone Interview for Cognitive Status score <32; Clinical Dementia Rating [CDR] global score >0.5 and CDR sum of box scores >1). Participants were willing to be randomized and attend community-based intervention group meetings.

Trial Procedures

Eligibility was determined via mailed outreach, phone screening, and in-person visits (Supplement 1).¹⁹ Clinic assessments, including blood collection and medical review, were completed at baseline and every 6 months for 2 years. Participants could join ancillary studies of brain imaging,²² home-based sleep assessments,²³ peripheral/neurovascular assessments,²⁴ and gut microbiome analyses.

Randomization and Masking

Randomization was stratified by site using a centrally generated, variable-length algorithm in blocks of 4 or 6, securely embedded in the study database. Only data coordinating center personnel, the intervention oversight committee, and relevant site staff (intervention teams, study clinicians) were unmasked to intervention assignment. All team members were masked to outcome data except site staff responsible for assessments or data entry, the lead neuropsychologist and outcomes project manager, and the data coordinating center. Masked personnel had restricted database access and were ex-

cluded from unmasking discussions. Participants were reminded at clinic visits to avoid disclosing group assignment. Masking procedures were effective; only 1 examiner was unmasked to a participant's group assignment. No interim outcomes analyses by intervention assignment were conducted before initiation of study closeout.


Interventions

Intervention details are published¹⁹ and described in the trial protocol (Supplement 1). An overview is provided in Figure 1. Both interventions promoted increased physical and cognitive activity, healthy diet, social engagement, and cardiovascular monitoring but differed in structure, intensity, and accountability. Participants were randomized 1:1 to the structured or self-guided intervention (Figure 2) and assigned to peer teams (10-15 participants) for support. Navigators from the Alzheimer's Association supported both groups. Structured group teams received additional support from certified interventionists.

Structured Lifestyle Intervention

The structured group attended 38 facilitated team meetings over 2 years with structured intervention navigators and interventionists and received activity plans with quantifiable adherence metrics (Supplement 1). The intervention included aerobic (4 days per week, 30-35 minutes per session), resistance (2 days per week, 15-20 minutes per session), and flexibility (2 days per week, 10-15 minutes per session) training, primarily at a community facility (eg, YMCA); guidelines for

Figure 2. Participant Flow in US POINTER



^aThe modified Telephone Interview for Cognitive Status (TICSm) is a test of global cognitive function with a range of 0 to 50, with higher scores reflecting better cognition. Participants scoring ≥ 32 were deemed cognitively eligible.

^bPotential participants could be ineligible for more than 1 reason. Only reasons that excluded ≥ 500 persons are shown.

^cThe Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet screener scores range from 0 to 14 and assess consumption of food groups linked to cognitive health in older adults. Scores ≤ 9.0 , indicating suboptimal adherence, were required for study eligibility.

^dThe risk score for cognitive decline was based on having a sedentary lifestyle

(1 point; Telephone Assessment of Physical Activity, <60 min/wk at moderate intensity); having a suboptimal diet (1 point; MIND diet screener score ≤ 9); and at least 2 of the following: first-degree family history of memory impairment (1 point); elevated cardiometabolic risk (1 point; systolic blood pressure ≥ 125 mm Hg, low-density lipoprotein cholesterol ≥ 115 mg/dL [2.98 mmol/L], or hemoglobin A_{1c} $\geq 6.0\%$); self-identified American Indian or Alaska Native, Black, African American, or African, or Middle Eastern or North African race or Hispanic, Latinx, or Spanish ethnicity (1 point); age 70 to 79 years (1 point); or male sex (1 point).

^eRandomization was stratified by clinical site.

following the MIND diet (components listed in eTable 1 in Supplement 3); weekly web-based cognitive training using BrainHQ (3 times per week, 15-20 minutes per session); and biannual review of abnormal laboratory results (blood pressure, cholesterol, hemoglobin A_{1c}) with reinforcement of intervention goals. Monthly rebates of up to \$10 for purchase of

blueberries were offered to participants in the structured lifestyle intervention group.

Self-Guided Lifestyle Intervention

The self-guided group received publicly available education materials and was encouraged to make lifestyle changes that

best suited personal needs and schedules. Gift cards (\$75) were provided at team meetings to support behavior change. Self-guided intervention navigators offered encouragement, without goal-directed coaching, during 6 peer team meetings held over 2 years. Annual guideline-based health monitoring was conducted during clinic visits.

Outcomes

The primary outcome was a global cognitive composite score, constructed from equally weighted domain composites of executive function, episodic memory, and processing speed—domains previously shown to improve with multidomain lifestyle interventions.^{8,12} Composite scores are more sensitive to subtle cognitive changes in cohorts whose cognition is largely intact but who are at risk of cognitive decline,^{25,26} and these scores provide greater statistical power than individual test scores.²⁷ The 3 domain composites, which served as prespecified secondary outcomes, were derived from tests of the modified Neuropsychological Test Battery,²⁸ which include the Free and Cued Selective Reminding Test (FCSRT), Story Recall, Visual Paired Associates, Number Span, Word Fluency, Trail-Making Test Parts A and B (TMT-A and TMT-B), and Digit Symbol Substitution Test (DSST). The domain composites of executive function (Number Span, Fluency, TMT-B), episodic memory (FCSRT, Story Recall, Visual Paired Associates), and processing speed (TMT-A, DSST) were constructed from z-transformed test scores (see [Supplement 2](#) for scoring details). Assessments were administered during clinic visits at baseline and every 6 months for 2 years.

The trial protocol ([Supplement 1](#)) specifies additional secondary outcomes—including other cognitive measures, functional outcomes, and self-reported lifestyle activities—that will be reported in future publications.

Adjudication of Baseline Cognitive Status

Participants with baseline CDR scores of 0.5 or Mini-Mental State Examination scores of 26 or lower were flagged for central adjudication of possible mild cognitive impairment or AD and related dementias by an expert panel. Review materials included baseline cognitive test scores, questionnaires about cognitive concerns and depression, relevant medical and medication histories, and responses on the CDR. If a study partner was unavailable, the study clinician provided input on CDR global score. Each case was discussed until the panel majority agreement was reached on 1 of the following: no cognitive impairment, mild cognitive impairment, probable dementia, or cannot classify.

Sample Size

The target enrollment ($n = 2000$) with 2 years of follow-up provided at least 85% power at a 2-sided $\alpha = .05$ to detect an 0.030-SD per-year difference in slopes (based on FINGER results⁸) for the primary outcome. Simulations of cognitive trajectories in the Women's Health Initiative Study of Cognitive Aging²⁹ were used to project power ([Supplement 2](#)). One interim analysis (pooled across intervention groups) confirmed assumptions about variances, longitudinal correlations, and

missing data. As the interim analysis was masked to group assignment, no type I error penalty was applied.

Safety

Adverse events were ascertained at 6-month clinic visits using a standardized query by unmasked assessors. Events could also be spontaneously reported (volunteered) between visits to site staff or intervention personnel. If reported both ways, events were coded as ascertained. The *Medical Dictionary for Regulatory Activities (MedDRA)* was used for coding (up to 3 codes per event) by the data coordinating center. The masked trial safety officer and unmasked site clinicians assessed relationship to the intervention.

Serious adverse events were defined as fatal/life-threatening, causing disability, requiring hospitalization, or deemed clinically significant by investigators. Prespecified conditions of interest—such as injurious falls, fractures, musculoskeletal pain, gastrointestinal symptoms, and COVID-19 test result positivity—were reported as nonserious adverse events (eTable 2 in [Supplement 3](#)).

Statistical Analysis

All data from all participants were analyzed according to intervention assignment. Results are reported as point estimates (mean differences across groups) and 95% confidence intervals. Test scores were converted to z scores using the baseline mean and standard deviation. Composite scores were the mean of individual test z scores renormalized to a standard deviation of 1 at baseline. See [Supplement 2](#) for more details.

Trajectories of change in cognitive z scores from baseline were portrayed using linear contrasts from a mixed-effects model for repeated measures.²² Repeated test administration is known to produce practice effects, in which scores may initially improve and then plateau or decline with subsequent testing. The primary inference model included covariate adjustment to account for these effects and the possibility that practice effects varied by age.

Time (clinic visit) in the primary inference was coded as 0, 0.5, 1.0, 1.5, and 2.0 years and treated as a continuous variable, with values assigned that best aligned with the scheduled clinic visits (ie, baseline and months 6, 12, 18, and 24). Independent variables included participant, intervention assignment, time, site (stratification factor), baseline age, test version (if more than 1 version was used), a counter for number of prior assessments (ie, 0, 1, 2, 3, etc, to control for practice effects), and a counter $\times$ age interaction. Missing data were assumed to be missing at random. Two-tailed type I error was set at .05. An intervention $\times$ time interaction tested whether covariate-adjusted slopes differed between groups (as in FINGER⁸). Models used restricted maximum likelihood with an unstructured covariance. Inverse probability weighting was used to assess the impact of missing data, and post hoc supporting analyses evaluated the sensitivity of results to model assumptions (eAppendix 1 in [Supplement 3](#)).

Consistency of effects across domain composites for episodic memory, executive function, and processing speed were examined using similar models as prespecified secondary outcomes in the statistical analysis plan, and results are reported with 95% confidence intervals. Prespecified secondary

Table 1. Baseline Participant Characteristics

Characteristics	Structured (n = 1056)	Self-guided (n = 1055)
Age, mean (SD), y	68.3 (5.2)	68.1 (5.2)
Aged ≥75 y, No. (%)	143 (13.5)	131 (12.4)
Sex, No. (%)		
Female	721 (68.3)	734 (69.6)
Male	335 (31.7)	321 (30.4)
Race and ethnicity, No. (%) ^a		
American Indian or Alaska Native	3 (0.3)	1 (0.1)
Asian or Asian American	33 (3.1)	22 (2.1)
Black, African American, or African	161 (15.2)	179 (17.0)
Hispanic, Latinx, or Spanish	63 (6.0)	61 (5.8)
Middle Eastern or North African	1 (0.1)	1 (0.1)
White or European American	725 (68.7)	729 (69.1)
Multiple	55 (5.2)	51 (4.8)
Other	10 (0.9)	6 (0.6)
Prefer not to respond	5 (0.5)	5 (0.5)
Highest level of education, No. (%)		
High school	54 (5.1)	56 (5.4)
Some college/associate's degree	257 (24.5)	268 (25.6)
Bachelor's degree	352 (33.6)	372 (35.6)
Postgraduate degree	386 (36.8)	349 (33.4)
Body mass index, median (IQR) ^b	30.0 (26.0-33.3)	30.0 (25.9-33.4)
Blood pressure, mean (SD), mm Hg		
Systolic ^c	131.5 (15.9)	130.7 (16.0)
Diastolic ^d	76.8 (9.4)	76.6 (9.4)
Hemoglobin A _{1c} , mean (SD), % ^e	5.9 (0.7)	5.9 (0.7)
Cholesterol, mean (SD), mg/dL		
Total ^f	192.7 (42.5)	194.7 (42.6)
LDL-C ^g	111.6 (36.0)	113.1 (36.2)
FRS CVD risk and prevalence, No. (%) ^h		
Low (<10%)	289 (27.4)	331 (31.4)
Medium (10%-20%)	344 (32.6)	334 (31.7)
High (>20%)	261 (24.7)	268 (25.4)
Prevalent cardiovascular disease	162 (15.3)	119 (11.3)

(continued)

subgroup analyses examined consistency of the intervention effect on the primary outcome by baseline cognitive function (median split of global cognitive composite score) and *APOE* ε4 carrier status (yes or no). Exploratory subgroup analyses were also examined by sex (female or male), age (<70 or ≥70 years), and baseline cardiometabolic health (Framingham risk: low [<10%], medium [10%-20%], or high [>20%]³⁰; or prevalent cardiovascular disease: self-reported myocardial infarction, cardiac arrest, congestive heart failure, uncontrolled arrhythmia, uncontrolled angina, stent placement, angioplasty, coronary artery bypass graft surgery, valve replacement, deep vein thrombosis or pulmonary embolism, stroke, or transient ischemic attack). Results of subgroup analyses are reported with 95% confidence intervals and nominal *P* values.

Table 1. Baseline Participant Characteristics (continued)

Characteristics	Structured (n = 1056)	Self-guided (n = 1055)
<i>APOE</i> ε4 carrier, No. (%) ⁱ	322 (30.6)	338 (32.2)
Family history of memory loss, No. (%)	837 (79.3)	836 (79.2)
MIND diet score, mean (SD) ^j	7.0 (1.4)	7.1 (1.4)
TICS _m score, mean (SD) ^k	37.6 (3.4)	37.6 (3.2)
MMSE score, median (IQR) ^l	29 (28-30)	29 (28-30)
Geriatric Depression Scale score, median (IQR) ^m	1 (0-2)	1 (0-3)
Adjudicated mild cognitive impairment, No. (%) ⁿ	52 (4.9)	47 (4.5)

SI conversion: To convert total cholesterol and LDL-C to millimoles per liter, multiply by 0.0259.

^a Race and ethnicity were self-identified by participants on a questionnaire, and multiple selections were permitted. If a participant indicated "none of the above describes me," race and ethnicity were coded as "other."

^b Body mass index is calculated as weight in kilograms divided by height in meters squared: overweight was defined as 25 to 29.9; obese, ≥30.0.

^c Elevated systolic blood pressure was defined as ≥130 mm Hg.

^d Elevated diastolic blood pressure was defined as ≥80 mm Hg.

^e Elevated hemoglobin A_{1c} was defined as >5.6%.

^f Elevated total cholesterol was defined as ≥200 mg/dL.

^g Elevated low-density lipoprotein cholesterol (LDL-C) was defined as ≥100 mg/dL.

^h Cardiovascular disease (CVD) risk was estimated using the Framingham risk score (FRS) to identify low (<10%), medium (10%-20%), and high (>20%) risk based on D'Agostino et al.³⁰ Prevalent CVD describes participants who reported myocardial infarction, cardiac arrest, congestive heart failure, uncontrolled arrhythmia, uncontrolled angina, stent placement, angioplasty, coronary artery bypass graft surgery, valve replacement, deep vein thrombosis or pulmonary embolism, stroke, or transient ischemic attack at baseline.

ⁱ *APOE* ε4 carrier status includes *APOE* genotypes 2/4, 3/4, and 4/4.

^j Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet scores range from 0 to 14, with higher scores reflecting higher adherence and degree to which epidemiological evidence indicates greater brain health in older adults.

^k The Modified Telephone Interview for Cognitive Status (TICS_m) (unadjusted scores) is a test of global cognitive function ranging from 0 to 50, with higher scores reflecting better performance.

^l Mini-Mental State Examination (MMSE) scores range from 0 to 30, with higher scores reflecting higher overall cognitive function.

^m The Geriatric Depression Scale is a self-administered questionnaire ranging from 0 to 15, with higher scores reflecting worse mood.

ⁿ Cognitive status at baseline was adjudicated to identify mild cognitive impairment or dementia by an expert panel using all cognitive, medical, and self-reported data.

Adverse event rates were compared using Poisson regression. Analyses were performed using SAS version 9.4 (SAS Institute Inc).

Results

Figure 2 shows participant flow through the trial. Of 13 285 individuals who initiated screening, 2111 were randomized to the structured (n = 1056) or self-guided (n = 1055) interventions (see eTable 3 in Supplement 3 for allocation by clinical site) from May 2019 to March 2023. Most exclusions were

Table 2. Cognitive Outcomes Based on Mixed-Effects Models for Repeated Measures Comparing Annual Rate of Change (Slope) Between Intervention Groups, With Covariate Adjustment

Outcomes	Mean rate of change per year, SD (95% CI)		Mean between-group difference in rate of change per year (95% CI) ^a	P value
	Structured	Self-guided		
Global cognitive function composite (primary outcome)	0.243 (0.227-0.258)	0.213 (0.198-0.229)	0.029 (0.008 to 0.050)	.008
Individual components of the global cognitive function composite outcome				
Executive function	0.160 (0.140-0.180)	0.122 (0.102-0.141)	0.037 (0.010 to 0.064)	
Episodic memory	0.250 (0.230-0.270)	0.239 (0.219-0.259)	0.009 (−0.019 to 0.037)	
Processing speed	0.178 (0.158-0.198)	0.155 (0.136-0.175)	0.023 (−0.004 to 0.050)	

^a Adjusted for site (stratification factor), baseline age, test version (if >1 version used), number of prior assessments (to control for practice effects), and number of prior assessments × age interaction.


due to high MIND diet score, not being sedentary, low cognitive function, age, or not meeting other prespecified risk criteria. Despite a pause on in-person visits from March to July 2020 due to COVID-19, enrollment remained on track (eFigure 1 in Supplement 3). Overall, 43 structured and 39 self-guided participants discontinued the intervention. The last participant exited on May 14, 2025. A total of 1941 participants (92%) completed month 6 clinic assessments, 1898 (90%) completed month 12 assessments, 1847 (87%) completed month 18 assessments, and 1879 (89%) completed month 24 assessments.

Both intervention groups were similar in demographics and risk factors for cognitive decline (Table 1). Overall, the cohort was largely cognitively healthy, with a median Mini-Mental State Examination score of 29 (IQR, 28-30), and less than 5% of participants had mild cognitive impairment adjudicated at baseline. The mean age was 68.2 (SD, 5.2) years, 68.9% were female, 30.8% represented racial and ethnic minority groups, 30.0% did not have a college degree, and the mean modified Telephone Interview for Cognitive Status score was 37.6 (SD, 3.3). Baseline cognitive test scores were comparable across groups (eTable 4 in Supplement 3).

Mean intervention adherence measured using team meeting attendance exceeded the 80% goal for both groups, with 91.0% for structured and 94.8% for self-guided (eFigure 2A in Supplement 3). Attendance varied slightly among subgroups (eFigure 2B-H in Supplement 3) but remained high overall.

Global cognitive composite scores increased over time for both groups at a mean rate of 0.243 SD (95% CI, 0.227-0.258) per year for structured and 0.213 SD (95% CI, 0.198-0.229) per year for self-guided after prespecified covariate adjustment. The mean difference in rate of change in these scores between groups—the primary outcome—was 0.029 SD per year (95% CI, 0.008-0.050; $P = .008$) (Table 2 and Figure 3). Changes in unadjusted global composite z scores by intervention group are shown in eFigure 3 in Supplement 3. Results of supporting analyses are presented in eAppendix 1 in Supplement 3, which show no evidence that differential missing data and choice of statistical model biased findings.

Analyses of intervention effects on the primary outcome's constituent cognitive domains (prespecified secondary outcomes) showed greater improvement in executive function for the structured group vs the self-guided group


Figure 3. Change From Baseline in Global Cognitive Function Composite Score (Primary Outcome) by Structured vs Self-Guided Lifestyle Interventions

Mean changes from baseline for the global cognitive function composite score fitted using linear contrasts from a mixed-effects model for repeated measures including all available participant data. Global cognitive function composite z scores are scaled to have SD = 1, so nearly 70% of participants obtain a score within 1 SD of the mean. Higher values indicate improved performance relative to baseline. Whiskers indicate 95% CIs. Included are results from the per-protocol analysis to compare slopes (SDs per year) between groups after adjustment for clinical site, baseline age, practice effects, and test version. Mean rate of change over time per year (slope): structured group, 0.243 SD (95% CI, 0.227-0.258); self-guided group, 0.213 SD (95% CI, 0.198-0.229). See eFigure 3 in Supplement 3 for raw score box-and-whisker plots of the global and domain-specific composite scores.

by 0.037 SD (95% CI, 0.010-0.064) per year. Processing speed showed a similar pattern, with a difference of 0.023 SD (95% CI, −0.004 to 0.050) per year favoring the structured group, which did not reach statistical significance. Increases in episodic memory did not differ by intervention group at 0.009 SD (95% CI, −0.018 to 0.037) per year. These findings are summarized in Table 2, and unadjusted composite z scores by cognitive domain and intervention group are shown in eFigure 3 in Supplement 3.

The structured intervention effect on the primary outcome did not significantly differ by *APOE* ε4 carrier status ($P = .95$ for interaction) but appeared to be more potent for participants with lower baseline cognitive function (lower: 0.054 SD [95% CI, 0.024-0.084]; higher: 0.004 SD [95% CI, −0.025

Figure 4. Intervention Effects on Global Cognitive Function Composite Score (Primary Outcome) by Prespecified Subgroups



Changes per year in adjusted global cognitive composite z scores (SDs) for prespecified subgroups by intervention group assignment and differences between groups after adjustment for clinical site, baseline age, practice effects, and test version. The raw *P* values (not adjusted for multiple comparisons)

compare changes over time for levels within a subgroup and tests of interaction across subgroup levels by intervention group assignment to assess the consistency of relative intervention effects on the primary outcome.

to 0.034]; *P* = .02 for interaction). Results of exploratory subgroup analyses suggest consistent structured intervention effects by sex (*P* = .44 for interaction), age (*P* = .41 for interaction), and baseline cardiovascular health (*P* = .54 for interaction). These findings are summarized in **Figure 4**.

Fewer ascertained adverse events (collected by unmasked assessors during clinic visits) were reported for the structured group than the self-guided group (eTable 5A in [Supplement 3](#)). For serious adverse events, ascertained totals were 151 for structured and 190 for self-guided (difference, *P* = .03). The structured group had 9 serious adverse events judged as intervention related and 11 deaths; the self-guided group had 2 serious adverse events judged as intervention related and 5 deaths. For nonserious adverse events, ascertained totals were 1091 for structured and 1225 for self-guided (difference, *P* = .005). Volunteered nonserious adverse events were more common in the structured group (685 vs 140 in self-guided group), likely reflecting more frequent staff contact and thus more reporting opportunity. The most common *MedDRA* codes for serious adverse events and adverse events (eTable 5B-C in [Supplement 3](#)) showed low overall rates with some group differences: more infections, neoplasms, and kidney disorders in the structured group; more nervous system disorders in the self-guided group. A positive COVID-19 test result was the most common adverse event (669 [21.3%] of 3141 adverse events reported overall) and was more often reported in the structured group (380 events vs 289 events reported in the self-guided group), although no clustering related to team meetings was observed.

Discussion

The US POINTER trial yielded 3 principal findings. First, in a large cohort of older adults at elevated risk of cognitive decline associated with dementia, multidomain lifestyle interventions were delivered safely and with high adherence. Second, greater structure, accountability, and intervention intensity produced a statistically significant relative enhancement in cognitive benefit over 2 years. Third, this benefit was consistent across several key subgroups.

Both intervention groups showed cognitive improvement over 2 years; however, the structured intervention yielded greater benefit than the self-guided intervention. The upward cognitive trajectories in both groups showing improvement likely reflect, in part, practice effects—commonly observed in studies with repeat assessments,³¹ particularly at the second testing.³² Analyses were adjusted for number of prior assessments to help mitigate this influence.

Assessing clinical significance is challenging given the improvement observed in both groups and the potential influence of practice effects. The additional benefit of 0.029 SD per year for the structured intervention closely aligns with the protocol target of 0.030 SD per year, which was based on the effect size reported in the FINGER trial that also demonstrated reduced decline in activities of daily living³¹ (preserved independence) and lower incidence of chronic disease³³ (preserved health) with a similar multidomain intervention. Future analyses of POINTER data, including additional cognitive

measures, functional outcomes, fluid and imaging biomarkers, and longer-term cognitive trajectories, may help clarify the clinical significance and durability of these findings.

These results also raise considerations for public health implementation. Notably, the self-guided group improved despite lower resource demands and participant burden. However, the absence of a no-intervention control limits our ability to rule out alternative explanations for cognitive improvement at this time, including practice effects and general benefits of trial participation. Planned analyses from the extended 4-year follow-up and biomarker substudies²² will provide further insight into long-term impact and comparative effectiveness across groups.

The global cognitive composite was calculated as the mean of composite z scores for executive function, episodic memory, and processing speed. To provide context for interpreting the primary outcome, we examined domain composite trajectories across groups. These analyses indicated that executive function and processing speed were the primary contributors to the overall effect, whereas change in episodic memory did not differ between groups—a pattern also observed in the FINGER trial.⁸ Executive function may be especially responsive to behaviors that reduce cardiometabolic risk. Aerobic exercise is associated with improvements in executive function³⁴ and increased prefrontal gray matter volume,³⁵ while a Mediterranean diet may further enhance executive function via cardiovascular benefits.³⁶ Cognitive benefits did not differ between *APOE* ϵ 4 carriers and noncarriers, suggesting that lifestyle interventions may be effective even among individuals at elevated cardiovascular or genetic risk of dementia. Future analyses of expanded domain composites that incorporate additional measures may further clarify domain-specific contributions to the primary outcome.

This trial enrolled older adults at increased risk of cognitive decline due to sedentary behavior, suboptimal diet, family history of memory loss, and cardiometabolic risk factors. Participants were recruited from 5 different geographical US regions and represented diverse ethnoracial backgrounds. National data indicate that up to 35% of older adults do not meet physical activity guidelines,³⁷ 81% consume suboptimal diets,³⁸ and nearly 55% meet criteria for metabolic syndrome (≥ 3 risks).³⁹ These estimates highlight the prevalence of eligibility-targeted characteristics and support generalizability to the broader US population. Subgroup analyses (Figure 4) showed consistent benefits of the structured intervention over the self-guided intervention across *APOE* ϵ 4 carrier status, sex, age, and cardiometabolic health, reinforcing applicability to a heterogeneous at-risk population. The possibility of greater structured intervention benefit among individuals with lower cognitive function is intriguing but warrants further investigation.

Serious adverse events occurred at similar rates: 12% of structured participants and 14% of self-guided participants experienced at least 1 ascertained event. Voluntarily reported se-

rious adverse events were more common in the structured group ($n = 91$) than in the self-guided group ($n = 47$), likely reflecting more contact with study staff. In contrast, ascertained serious adverse events, collected during 6-month clinic visits, were less frequent for the structured group ($n = 151$) than for the self-guided group ($n = 190$). The structured group experienced more gastrointestinal disorders and infections; gastrointestinal symptoms may be related to dietary changes, although the higher rate of infections is unexplained. There were no notable group differences in ascertained serious adverse events related to musculoskeletal issues or fractures.

The structured intervention was considered higher intensity due to the frequency of team meetings (38 vs 6 in the self-guided group over 2 years) and the regular, intentional engagement expected for adherence to intervention activities. Participants were encouraged to practice healthy behaviors weekly to support long-term, sustainable change. Key components for implementation included regular facilitated team meetings and access to community-based resources (eg, exercise facilities), both of which could be feasibly delivered in real-world settings to support widespread health behavior change.

Strengths of this trial include its randomized design, recruitment of a diverse cohort, high retention, rigorous masking, standardized implementation, and strong intervention fidelity and adherence.

Limitations

This study has several limitations. First, generalizability may be limited by inclusion of only 5 sites, by selective enrollment criteria to enrich risk of cognitive decline, and by the requirement to be randomized and complete a 2-year trial with extensive phenotyping. Second, the trial was not powered to assess cognitive impairment or dementia outcomes. Third, the self-guided group did not serve as a true no-intervention control. Fourth, participants were unmasked to intervention assignment. Fifth, the durability, scalability, and long-term clinical significance of the intervention remain unknown. Sixth, although there is no evidence that missing data biased the findings, this possibility cannot be completely ruled out.

Conclusions

US POINTER demonstrated that multidomain lifestyle interventions can be safely and effectively delivered to older adults. Although global cognitive function improved for both intervention groups, greater benefit was observed with the structured multidomain intervention, which promoted regular physical exercise, adherence to the MIND diet, cognitive and social challenge, and health monitoring. Further research is needed to understand the clinical significance of this difference and assess longer-term clinical outcomes of both interventions.

ARTICLE INFORMATION

Accepted for Publication: July 10, 2025.

Published Online: July 28, 2025.
doi:10.1001/jama.2025.12923

Author Affiliations: Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina (Baker,

Cleveland, Wilmoth, Woolard); Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina (Espeland, Leng, Lovato, Felton, Garcia, Howard); Department of Public Health Sciences, University of California, Davis, Sacramento (Whitmer); Division of Medical and Scientific Relations, Alzheimer's Association, Chicago, Illinois (Snyder, Carrillo); Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts (Papp); Department of Neurology, Massachusetts General Hospital, Boston (Papp); Department of Neurology, Harvard Medical School, Boston, Massachusetts (Papp); Department of Neurology, Baylor College of Medicine, Houston, Texas (Yu, Pavlik); Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institute, Stockholm, Sweden (Kivipelto); Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland (Kivipelto); School of Public Health, Ageing Epidemiology Research Unit, Imperial College London, London, United Kingdom (Kivipelto); Kelsey Research Foundation, Houston, Texas (Alexander); Rhode Island Chapter, Alzheimer's Association, Providence (Antkowiak); Northern California and Northern Nevada Chapter, Alzheimer's Association, San Jose (Day); Houston and Southeast Texas Chapter, Alzheimer's Association, Houston (Elbein, McDonald); Department of Neurology, University of California, Davis, Sacramento (Tomaszewski Farias); Advocate Memory Center and the Advocate Aurora Research Institute, Advocate Aurora Health, Downers Grove, Illinois (Gitelman); Department of Clinical Nutrition, Rush University Medical Center, Chicago, Illinois (Graef); Department of Health and Exercise Science, Wake Forest University, Winston-Salem, North Carolina (Katula); Western Carolina Chapter, Alzheimer's Association, Charlotte, North Carolina (Lambert); Illinois Chapter, Alzheimer's Association, Chicago (Matongo); Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (Raman); Memory and Aging Program, Butler Hospital, and Warren Alpert Medical School of Brown University, Providence, Rhode Island (Salloway, Wing); Department of Psychiatry and Human Behavior, School of Medicine, Brown University, Providence, Rhode Island (Salloway); Departments of Clinical Nutrition and Family and Preventive Medicine, Rush University Medical Center, Chicago, Illinois (Tangney, Ventrelle); Department of Neurology, Wake Forest University School of Medicine, Winston-Salem, North Carolina (Williams); The Miriam Hospital, Providence, Rhode Island (Wing).

Author Contributions: Drs Baker and Espeland had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Baker and Espeland are co-first authors.

Concept and design: Baker, Espeland, Whitmer, Snyder, Leng, Papp, Kivipelto, Antkowiak, Farias, Felton, Graef, Katula, Lambert, Matongo, Raman, Salloway, Ventrelle, Wilmoth, Williams, Wing, Woolard, Carrillo.

Acquisition, analysis, or interpretation of data: Baker, Espeland, Whitmer, Snyder, Leng, Lovato, Papp, Yu, Kivipelto, Alexander, Cleveland, Day, Elbein, Farias, Felton, Garcia, Gitelman, Howard, Katula, Lambert, McDonald, Pavlik, Raman, Salloway, Tangney, Wilmoth, Williams, Wing, Woolard, Carrillo.

Drafting of the manuscript: Baker, Espeland,

Whitmer, Snyder, Leng, Lovato, Papp, Yu, Antkowiak, Felton, Howard, Katula, Wilmoth, Carrillo.

Critical review of the manuscript for important intellectual content: Baker, Espeland, Snyder, Leng, Papp, Yu, Kivipelto, Alexander, Antkowiak, Cleveland, Day, Elbein, Farias, Felton, Garcia, Gitelman, Graef, Howard, Katula, Lambert, Matongo, McDonald, Pavlik, Raman, Salloway, Tangney, Ventrelle, Wilmoth, Williams, Wing, Woolard, Carrillo.

Statistical analysis: Espeland, Whitmer, Leng, Lovato, Garcia, Howard, Raman.

Obtained funding: Baker, Espeland, Whitmer, Snyder, Kivipelto, Day, Elbein, Lambert, Carrillo.

Administrative, technical, or material support: Baker, Espeland, Snyder, Papp, Yu, Alexander, Antkowiak, Day, Elbein, Farias, Felton, Gitelman, Katula, Matongo, McDonald, Pavlik, Tangney, Ventrelle, Wilmoth, Williams, Woolard, Carrillo. **Supervision:** Baker, Snyder, Leng, Yu, Kivipelto, Antkowiak, Day, Elbein, Gitelman, Graef, Katula, Lambert, McDonald, Wing, Woolard, Carrillo.

Conflict of Interest Disclosures: Dr Espeland reported receipt of grants from the National Institutes of Health (NIH) and personal fees from Annovis Bio, Acumen Pharma, and Nestlé. Dr Whitmer reported receipt of grants from the NIH. Dr Leng reported receipt of grants from the Alzheimer's Association (outside the submitted work) and the NIH. Dr Yu reported receipt of grants from Biogen, Eisai, AriBio, Suven, and Novo Nordisk and nonfinancial support from Cognition Therapeutics. Dr Kivipelto reported serving on scientific advisory boards for Combinostics, Eisai, Eli Lilly, and Nestlé. Ms Alexander reported that her organization, Kelsey Research Foundation, conducts commercially sponsored clinical trials across various medical specialties; collaborates with and serves as a subcontractor on research studies with academic medical centers and other nonprofit research groups; and receives philanthropic funding to support research and organizational operations as well as specific support within the areas of cancer prevention, diagnosis and treatment, and education. Dr Gitelman reported receipt of fees from AbbVie, Eisai, and Lilly for advisory board membership (paid to institution) and receipt of grants from Bristol Myers Squibb, Cassava, Eisai, and Lilly. Dr Raman reported receipt of grants from the National Institute on Aging, the Alzheimer's Association, Eisai, and the American Heart Association (awarded to institution). Dr Salloway reported receipt of grants from the NIH. Dr Tangney reported receipt of royalties from UpToDate. Dr Snyder, Ms Antkowiak, Ms Day, Mr Elbein, Ms Lambert, Ms Matongo, Ms McDonald, and Dr Carrillo report being employees of the Alzheimer's Association. No other disclosures were reported.

Funding/Support: This study was supported by the Alzheimer's Association (POINTER-19-611541). The US Highbush Blueberry Council provided monthly rebates for participants assigned to the structured intervention.

Role of Funder/Sponsor: US POINTER was conceived and developed in partnership with the Alzheimer's Association. Drs Snyder and Carrillo, full-time employees of the Alzheimer's Association, participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and

approval of the manuscript; and decision to submit the manuscript for publication.

Meeting Presentation: Presented at the 2025 Alzheimer's Association International Conference; July 28, 2025; Toronto, Ontario, Canada.

Data Sharing Statement: See [Supplement 4](#).

Additional Contributions: We thank the study participants as well as their study partners who agreed to take part in this journey. We are indebted to them for their trust and their commitment to the study. We are deeply grateful to the study team (eAppendix 2 in [Supplement 3](#)) for their dedication to the trial and their exceptional care of participants. We thank the members of the data and safety monitoring board (no compensation): Cindy Carlsson, MD, MS, University of Wisconsin-Madison; Hiroko Dodge, PhD, Massachusetts General Hospital, Harvard Medical School; Richard Kryscio, PhD, University of Kentucky; Nicolas Musi, MD, Cedars-Sinai Medical Center; and Kathie Welsh-Bohmer, PhD, Duke University School of Medicine. We also thank the members of the Alzheimer's Association Scientific Advisory Board (no compensation): Barry Davis, ScM, PhD, University of Texas Health Science Center; Cynthia Lemere, PhD, Brigham and Women's Hospital, Harvard Medical School; Abby King, PhD, Stanford University; David Knopman, MD, Mayo Clinic; Kristina McLinden, PhD, National Institutes of Health, National Institute on Aging; Thomas Mosley, PhD, University of Mississippi Medical Center; David Reuben, MD, David Geffen School of Medicine at the University of California, Los Angeles; Mary Sano, PhD, Icahn School of Medicine at Mount Sinai; and Consuelo Wilkins, MD, MSCI, Vanderbilt University Medical Center.

REFERENCES

1. Alzheimer's Association. 2025 Alzheimer's Disease Facts and Figures. Accessed July 14, 2025. <https://www.alz.org/alzheimers-dementia/facts-figures>
2. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology*. 2007;69(24):2197-2204. doi:10.1212/01.wnl.0000271090.28148.24
3. Cummings JL, Osse AML, Kinney JW. Alzheimer's disease: novel targets and investigational drugs for disease modification. *Drugs*. 2023;83(15):1387-1408. doi:10.1007/s40265-023-01938-w
4. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
5. Sims JR, Zimmer JA, Evans CD, et al; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA*. 2023;330(6):512-527. doi:10.1001/jama.2023.13239
6. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. *J Prev Alzheimers Dis*. 2023;10(3):362-377. doi:10.14283/jpad.2023.30
7. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. *Lancet*. 2024;404(10452):572-628. doi:10.1016/S0140-6736(24)01296-0

8. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet*. 2015;385(9984):2255-2263. doi:10.1016/S0140-6736(15)60461-5
9. Kivipelto M, Mangialasche F, Snyder HM, et al. World-Wide FINGERS Network: a global approach to risk reduction and prevention of dementia. *Alzheimers Dement*. 2020;16(7):1078-1094. doi:10.1002/alz.12123
10. Brodaty H, Chau T, Heffernan M, et al. An online multidomain lifestyle intervention to prevent cognitive decline in at-risk older adults: a randomized controlled trial. *Nat Med*. 2025;31(2):565-573. doi:10.1038/s41591-024-03351-6
11. Yaffe K, Barnes DE, Rosenberg D, et al. Systematic Multi-Domain Alzheimer's Risk Reduction Trial (SMARTT): study protocol. *J Alzheimers Dis*. 2019;70(s1):S207-S220. doi:10.3233/JAD-180634
12. Oki Y, Osaki T, Kumagai R, et al. An 18-month multimodal intervention trial for preventing dementia: J-MINT PRIME Tamba. *Alzheimers Dement*. 2024;20(10):6972-6983. doi:10.1002/alz.14170
13. Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. *Lancet*. 2016;388(10046):797-805. doi:10.1016/S0140-6736(16)30950-3
14. Zülke AE, Pabst A, Luppä M, et al. A multidomain intervention against cognitive decline in an at-risk-population in Germany: results from the cluster-randomized AgeWell.de trial. *Alzheimers Dement*. 2024;20(1):615-628. doi:10.1002/alz.13486
15. Andrieu S, Guyonnet S, Coley N, et al; MAPT Study Group. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. *Lancet Neurol*. 2017;16(5):377-389. doi:10.1016/S1474-4422(17)30040-6
16. Sakurai T, Sugimoto T, Akatsu H, et al; J-MINT Study Group. Japan-Multimodal Intervention Trial for the prevention of dementia: a randomized controlled trial. *Alzheimers Dement*. 2024;20(6):3918-3930. doi:10.1002/alz.13838
17. Moon SY, Park YK, Jeong JH, et al. South Korean study to prevent cognitive impairment and protect brain health through multidomain interventions via face-to-face and video communication platforms in mild cognitive impairment (SUPERBRAIN-MEET): a randomized controlled trial. *Alzheimers Dement*. 2025;21(2):e14517. doi:10.1002/alz.14517
18. Soldevila-Domenech N, Ayala-Garcia A, Barbera M, et al. Adherence and intensity in multimodal lifestyle-based interventions for cognitive decline prevention: state-of-the-art and future directions. *Alzheimers Res Ther*. 2025;17(1):61. doi:10.1186/s13195-025-01691-0
19. Baker LD, Snyder HM, Espeland MA, et al; US POINTER Study Group. Study design and methods: US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (US POINTER). *Alzheimers Dement*. 2024;20(2):769-782. doi:10.1002/alz.13365
20. Whitmer RA, Baker LD, Carrillo MC, et al; US POINTER Study Group. Baseline characteristics of the US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (US POINTER): successful enrollment of a diverse clinical trial cohort at risk for cognitive decline. *Alzheimers Dement*. 2025;21(6):e70351. doi:10.1002/alz.70351
21. Boutron I, Altman DG, Moher D, Schulz KF, Ravaut P; CONSORT NPT Group. CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts. *Ann Intern Med*. 2017;167(1):40-47. doi:10.7326/M17-0046
22. Harrison TM, Ward T, Taggett J, et al; US POINTER Study Group. The POINTER imaging baseline cohort: associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition. *Alzheimers Dement*. 2025;21(1):e14399. doi:10.1002/alz.14399
23. Molina-Henry DP, Baker LD, Woolard N, et al; US POINTER Study Group. Pointer-ZZZ: sleep ancillary to US Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk of Alzheimer's disease. *Alzheimers Dement*. 2020;16(S10):e041440. doi:10.1002/alz.041440
24. Brinkley TE, Garcia KR, Mitchell GF, et al. The US POINTER neurovascular ancillary study: study design and methods. *Alzheimers Dement*. 2025;21(2):e14574. doi:10.1002/alz.14574
25. Langbaum JB, Ellison NN, Caputo A, et al. The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease. *Alzheimers Res Ther*. 2020;12(1):66. doi:10.1186/s13195-020-00633-2
26. Malek-Ahmadi M, Chen K, Perez SE, He A, Mufson EJ. Cognitive composite score association with Alzheimer's disease plaque and tangle pathology. *Alzheimers Res Ther*. 2018;10(1):90. doi:10.1186/s13195-018-0401-z
27. Jonaitis EM, Kosciak RL, Clark LR, et al. Measuring longitudinal cognition: individual tests versus composites. *Alzheimers Dement (Amst)*. 2019;11:74-84. doi:10.1016/j.dadm.2018.11.006
28. Papp KV, Farias ST, Howard M, et al; US POINTER Study Group. Baseline cognition and demographic, lifestyle, and cardiovascular risk factors in US POINTER. *Alzheimers Dement*. 2025;21(7):e70216. doi:10.1002/alz.70216
29. Espeland MA, Brunner RL, Hogan PE, et al; Women's Health Initiative Study of Cognitive Aging Study Group. Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. *J Am Geriatr Soc*. 2010;58(7):1263-1271. doi:10.1111/j.1532-5415.2010.02953.x
30. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008;117(6):743-753. doi:10.1161/CIRCULATIONAHA.107.699579
31. Wilson RS, Li Y, Bienias JL, Bennett DA. Cognitive decline in old age: separating retest effects from the effects of growing older. *Psychol Aging*. 2006;21(4):774-789. doi:10.1037/0882-7974.21.4.774
32. Zheng B, Udeh-Momoh C, Watermeyer T, et al. Practice effect of repeated cognitive tests among older adults: associations with brain amyloid pathology and other influencing factors. *Front Aging Neurosci*. 2022;14:909614. doi:10.3389/fnagi.2022.909614
33. Marengoni A, Rizzuto D, Fratiglioni L, et al. The effect of a 2-year intervention consisting of diet, physical exercise, cognitive training, and monitoring of vascular risk on chronic morbidity—the FINGER randomized controlled trial. *J Am Med Dir Assoc*. 2018;19(4):355-360. doi:10.1016/j.jamda.2017.09.020
34. Kramer AF, Colcombe S. Fitness effects on the cognitive function of older adults: a meta-analytic study—revisited. *Perspect Psychol Sci*. 2018;13(2):213-217. doi:10.1177/1745691617707316
35. Weinstein AM, Voss MW, Prakash RS, et al. The association between aerobic fitness and executive function is mediated by prefrontal cortex volume. *Brain Behav Immun*. 2012;26(5):811-819. doi:10.1016/j.bbi.2011.11.008
36. Rodrigues B, Coelho A, Portugal-Nunes C, et al. Higher adherence to the Mediterranean diet is associated with preserved white matter integrity and altered structural connectivity. *Front Neurosci*. 2020;14:786. doi:10.3389/fnins.2020.00786
37. Watson KB, Carlson SA, Gunn JP, et al. Physical inactivity among adults aged 50 years and older—United States, 2014. *MMWR Morb Mortal Wkly Rep*. 2016;65(36):954-958. doi:10.15585/mmwr.mm6536a3
38. Krebs-Smith SM, Pannucci TE, Subar AF, et al. Update of the Healthy Eating Index: HEI-2015. *J Acad Nutr Diet*. 2018;118(9):1591-1602. doi:10.1016/j.jand.2018.05.021
39. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. *JAMA*. 2015;313(19):1973-1974. doi:10.1001/jama.2015.4260